Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is positioned for strong growth potential in the medical device and diagnostics markets, with key products in cardiovascular and diabetes devices, adult and pediatric nutritional products, and diagnostic equipment. The company's recent launch of the Volt PFA system has shown success in both the US and Europe, with expectations of being a leading player in Europe and targeting a US launch in Q3. The company's strong investments in manufacturing and pipeline development show potential for continued success in the future. Overall, Abbott's well-rounded business model, strong cash generation, and focus on high-growth areas make it a compelling investment opportunity.

Bears say

Abbott Laboratories is facing several fundamental challenges that are negatively impacting its stock outlook. These include a highly competitive market for its medical devices and diagnostics products, potential market shifts due to healthcare policy changes, and risks from tariffs and litigation. The company's nutritional products segment has also seen declining sales and is undergoing a transition period which could further impact its revenue and profitability. While the company has made efforts to drive growth in high-growth areas such as diabetes and structural heart devices, there are concerns about the company's ability to sustain strong EPS growth and generate robust cash flow. These factors have contributed to a negative outlook for the company's stock.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.